In what is believed to be the first study of its kind, researchers at the University of Colorado, Denver will study the genes of those with a kind of epilepsy called Dravet Syndrome who have been treated with a strain of medical marijuana known as Charlotte’s Web.

While anecdotal evidence suggests Charlotte’s Web can be highly effective in treating such conditions, scientific investigation of the product has been stymied by federal drug laws that severely limit marijuana research.

The new study will recruit epilepsy patients who have already taken Charlotte’s Web. The patients will be divided into two groups—those who have seen seizure activity reduced by at least 50 percent on Charlotte’s Web and those who have had less dramatic or no results from taking the marijuana oil. Genetic analysis of the patients in both groups will then be performed in hopes of discovering what genetic components may cause a patient to be responsive to medical marijuana.

The study could potentially allow children with Dravet Syndrome to be genetically screened before taking Charlotte’s Web so parents could know ahead of time if their children would benefit.

Recruiting for the new study will begin within a month and data will be collected until February 2016.

Source: time.com


Leave a Reply

Your email address will not be published.

About Canna Magazine

This is the "wpengine" admin user that our staff uses to gain access to your admin area to provide support and troubleshooting. It can only be accessed by a button in our secure log that auto generates a password and dumps that password after the staff member has logged in. We have taken extreme measures to ensure that our own user is not going to be misused to harm any of our clients sites.

Category

Canna Science, Medical, Research

Tags

, , , , ,